Search results (1320)
« Back to PublicationsMNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 26 - 26
Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model
Reckzeh K. et al, (2012), Leukemia, 26, 1527 - 1536
Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials.
Stavraka C. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Gan H. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 189 - 189
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Coley HM. et al, (2012), Oncotarget, 3, 78 - 83
Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials
Pinato DJ. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ. et al, (2011), N Engl J Med, 365, 2484 - 2496
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S. et al, (2011), Cancer Chemother Pharmacol, 68, 1619 - 1628
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
Sabharwal A. et al, (2011), Melanoma Res, 21, 502 - 508
FLT3-ITDs Introduce a Myeloid Differentiation and Transformation Bias to Multipotent Lympho-Myeloid Progenitors
Mead AJ. et al, (2011), BLOOD, 118, 604 - 604
Germline Activating JAK2 V617I Mutation, in a Family with Hereditary Thrombocytosis
Mead AJ. et al, (2011), BLOOD, 118, 758 - 759
The Effect of Eltrombopag on Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway
Mitchell WB. et al, (2011), BLOOD, 118, 524 - 524
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
Psaila B. et al, (2011), J Thromb Haemost, 9, 2302 - 2310
Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the Head of the Pancreas
Neoptolemos J. et al, (2011), PANCREAS, 40, 1343 - 1343
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (vol 104, pg 1822, 2011)
Khan OA. et al, (2011), BRITISH JOURNAL OF CANCER, 105, 1252 - 1252
Erratum: Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (British Journal of Cancer (2011) 104 (1822-1827) DOI:10.1038/bjc.2011.154)
Khan OA. et al, (2011), British Journal of Cancer, 105
Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience
Rughani MG. et al, (2011), Journal of Plastic, Reconstructive and Aesthetic Surgery, 64, 1284 - 1290
Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience.
Rughani MG. et al, (2011), J Plast Reconstr Aesthet Surg, 64, 1284 - 1290
Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.
Kharazi S. et al, (2011), Blood, 118, 3613 - 3621
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Mitchell CL. et al, (2011), Cancer Chemother Pharmacol, 68, 631 - 641